ADVFN ADVFN

Hot Features

Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
Carisma Therapeutics Inc

Carisma Therapeutics Inc (CARM)

0,402
0,007
(1,77%)
0,4028
0,0008
(0,20%)
Après les heures de négociation: 1:58AM

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Statistiques et détails clés

Dernier
0,4028
( 1,97% )
Prix Achat
0,40
Prix Vente
0,4028
Volume échangé
657 226
0,3801 Fourchette du Jour 0,42
0,1417 Plage de 52 semaines 1,38
Cap du marché
Clôture Veille
0,395
Ouverture
0,39
Dernière Transaction
500
@
0.4028
(formt)
Dernière heure de transaction
Volume financier
US$ 260 708
VWAP
0,39668
Volume moyen (3 m)
15 046 454
Actions en circulation
41 788 096
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-0,27
Bénéfice par action (BPA)
-1,45
Chiffre d'affairess
19,63M
Bénéfice net
-60,48M

À propos de Carisma Therapeutics Inc

Carisma Therapeutics Inc. is a clinical-stage cell therapy company. The Company is focused on utilizing the Company's macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The Company has created a comprehensive cell t... Carisma Therapeutics Inc. is a clinical-stage cell therapy company. The Company is focused on utilizing the Company's macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The Company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells. The Company's lead product candidate, CT-0508, is a Chimeric Antigen Receptor Macrophage (CAR-M) to be evaluated in a human clinical trial and is intended to treat solid tumors that overexpress HER2. The Company's second product candidate, CT-0525, is also intended to treat solid tumors that overexpress HER2, is in preclinical development. Beyond CT-0508 and CT-0525, the Company has a pipeline of cell therapy assets in various stages of pre-clinical development. The Company is also developing in vivo CAR-M gene therapies. Show more

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Siège social
Wilmington, Delaware, USA
Fondé
-
Carisma Therapeutics Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker CARM. Le dernier cours de clôture d'Carisma Therapeutics était de US$0,40. Au cours de la dernière année, les actions de Carisma Therapeutics ont été négociées dans une fourchette de prix de US$ 0,1417 à US$ 1,38.

Carisma Therapeutics compte actuellement 41 788 096 actions en circulation. La capitalisation boursière d'Carisma Therapeutics est de US$16,51 million. Carisma Therapeutics a un ratio cours/bénéfice (ratio PE) de -0.27.

CARM Dernières nouvelles

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10.03248.747300215980.37040.42670.3696934010.40735253CS
4-0.3496-46.46464646460.75241.270.369455464611.03840449CS
120.179880.62780269060.2231.270.1417150464540.98822876CS
26-0.1172-22.53846153850.521.270.141772487910.97611868CS
52-0.8272-67.25203252031.231.380.141736563120.97242598CS
156-5.3872-93.04317789295.799.76620.141717139231.21088676CS
260-5.3872-93.04317789295.799.76620.141717139231.21088676CS

CARM - Frequently Asked Questions (FAQ)

What is the current Carisma Therapeutics share price?
The current share price of Carisma Therapeutics is US$ 0,4028
How many Carisma Therapeutics shares are in issue?
Carisma Therapeutics has 41 788 096 shares in issue
What is the market cap of Carisma Therapeutics?
The market capitalisation of Carisma Therapeutics is USD 16,51M
What is the 1 year trading range for Carisma Therapeutics share price?
Carisma Therapeutics has traded in the range of US$ 0,1417 to US$ 1,38 during the past year
What is the PE ratio of Carisma Therapeutics?
The price to earnings ratio of Carisma Therapeutics is -0,27
What is the cash to sales ratio of Carisma Therapeutics?
The cash to sales ratio of Carisma Therapeutics is 0,83
What is the reporting currency for Carisma Therapeutics?
Carisma Therapeutics reports financial results in USD
What is the latest annual turnover for Carisma Therapeutics?
The latest annual turnover of Carisma Therapeutics is USD 19,63M
What is the latest annual profit for Carisma Therapeutics?
The latest annual profit of Carisma Therapeutics is USD -60,48M
What is the registered address of Carisma Therapeutics?
The registered address for Carisma Therapeutics is CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Carisma Therapeutics website address?
The website address for Carisma Therapeutics is www.carismatx.com
Which industry sector does Carisma Therapeutics operate in?
Carisma Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
PROKProKidney Corporation
US$ 3,72
(513,36%)
340,03M
NDRAENDRA Life Sciences Inc
US$ 8,30
(140,12%)
90,54M
BTCSBTCS Inc
US$ 5,90
(110,71%)
134,33M
IROHIron Horse Acquisition Corporation
US$ 10,05
(68,34%)
5,58M
GAMEGameSquare Holdings Inc
US$ 1,54
(58,76%)
29,07M
PHHPark Ha Biological Technology Company Ltd
US$ 2,99
(-92,71%)
8,92M
ABVEAbove Food Ingredients Inc
US$ 0,4425
(-34,85%)
4,57M
UBXUNITY Biotechnology Inc
US$ 0,20
(-33,44%)
3,84M
GIBOGIBO Holdings Ltd
US$ 0,0416
(-33,33%)
216,49M
BGLBlue Gold Limited
US$ 53,68
(-28,11%)
168k
PROKProKidney Corporation
US$ 3,72
(513,36%)
340,05M
GIBOGIBO Holdings Ltd
US$ 0,0416
(-33,33%)
216,49M
LCIDLucid Group Inc
US$ 2,295
(8,77%)
216,16M
GVHGlobavend Holdings Ltd
US$ 0,0867
(6,25%)
216,02M
ZVSAZyVersa Therapeutics Inc
US$ 0,775
(17,37%)
208M
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock